Fig. 2
Long-term monitoring of HBV-specific cells following multiple administrations (day 1, 8, 15, 22, 29, 36, and 43) up to 68 days post-injection. Cynomolgus monkeys were injected subcutaneously with a low dose (1.0 × 109 VP/animal), mid dose (1.0 × 1010 VP/animal), and high dose (1.0 × 1011 VP/animal) of Ad-HBV, or with an empty Ad-null vector (1.0 × 1011 VP/ animal); an equal volume of saline was injected as a negative control. HBV antigen-specific cells were monitored and quantified by interferon-γ (IFNγ) ELISpot assays conducted at day 7(a), 35(b), 45(c), and 68(d) post-injection using peripheral blood mononuclear cells (PBMCs) respectively stimulated by HBV peptide pools (Core, Env, pol8, pol11, and pol13) or irrelevant peptides (DLM). *p < 0.05, **p < 0.01 vs. vehicle control